Cargando…

Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis

INTRODUCTION: Interleukin-35 (IL-35) is a newly defined potent anti-inflammatory cytokine that is predominantly produced by regulatory T cells, and pentraxin-3 belongs to the acute-phase proteins. AIM: To measure the serum IL-35 and pentraxin-3 levels in the early phase of mild acute pancreatitis (A...

Descripción completa

Detalles Bibliográficos
Autores principales: Aksoy, Evrim Kahramanoğlu, Sapmaz, Ferdane Pirinççi, Doğan, Özlem, Göktaş, Zeynep, Uzman, Metin, Nazlıgül, Yaşar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444112/
https://www.ncbi.nlm.nih.gov/pubmed/30944677
http://dx.doi.org/10.5114/pg.2019.83425
_version_ 1783407964051210240
author Aksoy, Evrim Kahramanoğlu
Sapmaz, Ferdane Pirinççi
Doğan, Özlem
Göktaş, Zeynep
Uzman, Metin
Nazlıgül, Yaşar
author_facet Aksoy, Evrim Kahramanoğlu
Sapmaz, Ferdane Pirinççi
Doğan, Özlem
Göktaş, Zeynep
Uzman, Metin
Nazlıgül, Yaşar
author_sort Aksoy, Evrim Kahramanoğlu
collection PubMed
description INTRODUCTION: Interleukin-35 (IL-35) is a newly defined potent anti-inflammatory cytokine that is predominantly produced by regulatory T cells, and pentraxin-3 belongs to the acute-phase proteins. AIM: To measure the serum IL-35 and pentraxin-3 levels in the early phase of mild acute pancreatitis (AP). MATERIAL AND METHODS: Eighty-three patients with mild AP and 30 healthy controls were included in the study. The serum levels of IL-35 and pentraxin-3 were measured by enzyme-linked immunosorbent assay upon admission and at the 48(th) hour after diagnosis. RESULTS: The mean value of serum IL-35 levels in patients with mild acute pancreatitis at admission was 5.91 ng/ml (4.21–7.90) and was significantly lower than those in healthy controls (25.53 ng/ml (12.79–54.73, p < 0.001)) and 48-hour value were (6.79 ng/ml (4.42–9.62) (p = 0.015)). The mean value of serum pentraxin-3 levels in patients at the time of admission was 6.75 ng/ml (4.42–9.62) and there was no significant difference from healthy controls, at 7.64 ng/ml (6.58–8.62, p > 0.05). Also there was no significant difference between the mean value at admission and the mean value at 48-hour, 6.75 ng/ml (4.74–9.06, p > 0.05). CONCLUSIONS: Interleukin-35 can be used in diagnosis and follow-up in patients with mild AP.
format Online
Article
Text
id pubmed-6444112
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-64441122019-04-03 Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis Aksoy, Evrim Kahramanoğlu Sapmaz, Ferdane Pirinççi Doğan, Özlem Göktaş, Zeynep Uzman, Metin Nazlıgül, Yaşar Prz Gastroenterol Original Paper INTRODUCTION: Interleukin-35 (IL-35) is a newly defined potent anti-inflammatory cytokine that is predominantly produced by regulatory T cells, and pentraxin-3 belongs to the acute-phase proteins. AIM: To measure the serum IL-35 and pentraxin-3 levels in the early phase of mild acute pancreatitis (AP). MATERIAL AND METHODS: Eighty-three patients with mild AP and 30 healthy controls were included in the study. The serum levels of IL-35 and pentraxin-3 were measured by enzyme-linked immunosorbent assay upon admission and at the 48(th) hour after diagnosis. RESULTS: The mean value of serum IL-35 levels in patients with mild acute pancreatitis at admission was 5.91 ng/ml (4.21–7.90) and was significantly lower than those in healthy controls (25.53 ng/ml (12.79–54.73, p < 0.001)) and 48-hour value were (6.79 ng/ml (4.42–9.62) (p = 0.015)). The mean value of serum pentraxin-3 levels in patients at the time of admission was 6.75 ng/ml (4.42–9.62) and there was no significant difference from healthy controls, at 7.64 ng/ml (6.58–8.62, p > 0.05). Also there was no significant difference between the mean value at admission and the mean value at 48-hour, 6.75 ng/ml (4.74–9.06, p > 0.05). CONCLUSIONS: Interleukin-35 can be used in diagnosis and follow-up in patients with mild AP. Termedia Publishing House 2019-03-12 2019 /pmc/articles/PMC6444112/ /pubmed/30944677 http://dx.doi.org/10.5114/pg.2019.83425 Text en Copyright: © 2019 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Aksoy, Evrim Kahramanoğlu
Sapmaz, Ferdane Pirinççi
Doğan, Özlem
Göktaş, Zeynep
Uzman, Metin
Nazlıgül, Yaşar
Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
title Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
title_full Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
title_fullStr Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
title_full_unstemmed Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
title_short Serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
title_sort serum interleukin-35 and pentraxin-3 levels in patients with mild acute pancreatitis
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444112/
https://www.ncbi.nlm.nih.gov/pubmed/30944677
http://dx.doi.org/10.5114/pg.2019.83425
work_keys_str_mv AT aksoyevrimkahramanoglu seruminterleukin35andpentraxin3levelsinpatientswithmildacutepancreatitis
AT sapmazferdanepirincci seruminterleukin35andpentraxin3levelsinpatientswithmildacutepancreatitis
AT doganozlem seruminterleukin35andpentraxin3levelsinpatientswithmildacutepancreatitis
AT goktaszeynep seruminterleukin35andpentraxin3levelsinpatientswithmildacutepancreatitis
AT uzmanmetin seruminterleukin35andpentraxin3levelsinpatientswithmildacutepancreatitis
AT nazlıgulyasar seruminterleukin35andpentraxin3levelsinpatientswithmildacutepancreatitis